Is Ardelyx, Inc. (ARDX) Overvalued?
We dive into why Ardelyx, Inc. (ARDX) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Ardelyx, Inc.’s (ARDX) Stock Is Down 14.58%
As of Friday, August 07, Ardelyx, Inc.’s ARDX share price has dipped by 14.58%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Ardelyx, Inc.’s (ARDX) Stock Is Down 17.15%
As of Friday, August 07, Ardelyx, Inc.’s ARDX share price has dipped by 17.15%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Ardelyx, Inc.’s (ARDX) Stock Is Down 6.04%
As of Monday, June 29, Ardelyx, Inc.’s ARDX share price has dipped by 6.04%, which has investors questioning if this is right time to buy.Michael Rose
Why Ardelyx, Inc.’s (ARDX) Stock Is Down 5.37%
As of Wednesday, May 13, Ardelyx, Inc.’s ARDX share price has dipped by 5.37%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | ARDX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $755.0 | $219.1 | 43% |
|
| Shares Out (Mil) | 248.1 | 53.4 | 80% |
|
| Institutional Ownership | 94.7% | 92.9% | 65% |
|
| Float (Mil) | 210.7 | 41.4 | 74% |
|
| Beta | 0.69 | 0.95 | 40% |
|
| Avg Daily Volume (000s) | 4,095 | 455 | 90% |
|
| Price Change (52-week) |
(50.0%) | 46.6% | 20% |
|
| Growth | ARDX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 121.7% | 13.2% | 99% |
|
| Net Income (5yr) | 8.2% | (10.1%) | 52% |
|
| EPS (5yr) | 24.6% | 15.8% | 75 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.0% | (15.7%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.015) | ($0.187) | $0.290 | |
| Month Ago EPS | ($0.014) | ($0.188) | $0.299 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $0.043 | ($0.052) | $0.515 | |
| Year/Year Chg | (77.6%) | (27.0%) | (404.3%) | |
| Financials | ARDX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $451 | $37 | 40% |
|
| Net Income (TTM) (Mil) | ($56) | ($44) | 15% |
|
| EPS (TTM) | ($0.227) | ($1.600) | 32% |
|
| Operating Cash Flow (TTM) (Mil) | ($17) | ($33) | 16% |
|
| Net Cash Flow (TTM) (Mil) | $7 | $1 | 54% |
|
| Long-Term Debt (Q1) (Mil) | $281 | $4 | 53% |
|
| Enterprise Value (Q1) (Mil) | $853 | $174 | 39% |
|
| Valuation | ARDX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.05 | 2.11 | 80% |
|
| P/E | na | 20.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ARDX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 75.0% | 66.0% | 85% |
|
| Net Margin | (12.4%) | (70.6%) | 20% |
|
| ROA | (10.7%) | (47.0%) | 25% |
|
| ROE | (38.6%) | (52.2%) | 18% |
|
| Liabilities to Assets | 74.1% | 29.6% | 70% |
|
| F-Score | 4 | 2 | 34% |
|
Ardelyx, Inc. did not pass any screens on 11/3/2026.
